サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1304543

抗生物質の世界市場-2023年～2030年

Global Antibiotics Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
抗生物質の世界市場-2023年～2030年
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

抗生物質の世界市場は、2022年には409億米ドルに達し、2030年には522億米ドルに達すると予測されています。抗生物質の世界市場は、2023年から2030年の予測期間中に3.1%のCAGRを示すと予測されています。

感染性疾患の増加、政府のイニシアチブ、消費量の増加、研究助成金の努力、有望な償還ガイドライン、製品の離脱、製品の許可、パートナーシップ、買収、提携、拡大などのような市場の帰結は、予測期間における抗生物質の世界市場の成長を後押しすると予想されます。抗生物質市場の主要な市場プレイヤーには、GlaxoSmithKline PLC、Johnson &Johnson Inc.Inc.、Pfizer Inc.などです。

市場力学

感染症の増加が抗生物質市場の成長を牽引

世界の感染症負担の増大は、予測期間における抗生物質世界市場の成長を促進すると予想されます。例えば、WHO感染症統計2022によると、2021年に世界で最近150万人以上がHIVに汚染されました。また、WHO Global Tuberculosis Report 2022によると、2021年に結核に罹患した人は世界で1,060万人と推定され、これは人口10万人当たり134人に相当します。全結核患者のうち、6.7％がHIV感染者でした。

地域別では、東南アジアが全体の45％、アフリカが23％、西太平洋が18％で、東地中海は8.1％、南北アメリカは2.9％、欧州は2.2％でした。

2021年には、HIV陰性者の死亡者数は140万人、HIV陽性者の死亡者数は約18万7,000人、合計160万人と評価され、最も妥当な評価である2020年の150万人、2019年の140万人から上昇し、2017年の水準に近づいた。

増加する研究資金が世界の抗生物質市場に成長機会をもたらすと期待される

研究資金の増加は、将来的に世界の抗生物質市場に有利な成長機会をもたらしています。例えば、2022年6月、英国政府のGlobal AMR Innovation Fund（GAMRIF）は、世界保健機関（WHO）が世界の健康と発展にとって最も重大な危険と認識している薬剤耐性疾患に対する独自の治療法を設計するGlobal Antibiotic Research and Development Partnership（GARDP）を維持するために450万ポンドを資金提供しました。

抗菌剤耐性は、予測期間中、世界の抗生物質市場を妨げると予測されます

抗生物質耐性と積極的な研究に関心を持つ希少なプレーヤーは、予測期間中の抗生物質市場の成長を妨げると予測されています。例えば、2021年のWHOの報告書では、抗菌剤の臨床および前臨床パイプラインは定常的なものであり、多国の要求を満たすには程遠いものと表現されています。2017年以降、認可された抗生物質はわずか12種類で、そのうち10種類は抗菌薬耐性（AMR）のメカニズムが特定された既存のカテゴリーからのものです。

COVID-19影響分析

COVID-19のパンデミックと世界各国でのロックダウンにより、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ戦争の影響分析

イエメンのコレラ、シリアのポリオ、アフガニスタンの麻疹など、戦争はどこでも感染症の発生や流行の基盤となります。実際、両世界大戦は結核による死亡者数を大幅に増加させました。戦争は、食糧不安や十分な換気が行われていない地域での過密状態など、結核にとって絶好の繁殖環境をもたらします。

これが、現在ウクライナ全土の防空壕で複数の人々が遭遇している憂慮すべき状況です。戦争はヘルスケアのインフラを破壊し、予防接種プログラムを潰し、質の高いケアへのアクセスを制限します。このため、病気の人の診断が遅れることが多く、その結果、より有害な複雑な病気が発生し、後方への感染の可能性が大きくなっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新製品の開発
      • 感染症の流行拡大
    • 抑制要因
      • 抗菌薬耐性
    • 機会
      • 資金調達イニシアティブ
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤クラス別

  • セファロスポリン
  • ペニシリン
  • フルオロキノロン
  • カルバペネム
  • マクロライド系
  • スルホンアミド系
  • アミノグリコシド系
  • その他

第8章 スペクトル別

  • 狭域スペクトル抗生物質
  • 広域スペクトル抗生物質

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別ダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • GlaxoSmithKline PLC
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Bayer Healthcare AG
  • Novartis AG
  • Sanofi SA
  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Otsuka Pharmaceutical Co. Ltd

第13章 付録

目次
Product Code: PH913

Market Overview

The Global Antibiotics Market reached US$ 40.9 billion in 2022 and is projected to witness lucrative growth by reaching US$ 52.2 billion by 2030. The Global Antibiotics Market is expected to exhibit a CAGR of 3.1% during the forecast period 2023-2030.

The increasing number of infectious disorders, government initiatives, increasing consumptions, research grant endeavors, promising reimbursement guidelines, and market consequences like product takeoffs, product permissions, partnerships, acquisitions, alliances, and expansion, among others are anticipated to boost the Global Antibiotics Market growth in the forecast period. The key market players in the Antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., and Pfizer Inc.

Market Dynamics

The Increasing Prevalence Of Infectious Diseases Drives The Growth Of The Antibiotics Market

The growing burden of infectious diseases globally is expected to boost the global antibiotics market growth in the forecast period. For instance, according to WHO communicable disease statistics 2022, HIV over 1.5 million individuals were recently contaminated with HIV worldwide in 2021. Also, according to the WHO Global Tuberculosis Report 2022, an estimated global total of 10.6 million individuals fell sick with TB in 2021, comparable to 134 cases per 100 000 inhabitants. Out of all TB patients, 6.7% were individuals living with HIV.

Region-wise, South-East Asia had 45% of total cases, Africa had 23% of cases, and the Western Pacific had 18% of the cases, with fewer percentages in the Eastern Mediterranean, around 8.1% of the cases, the Americas about 2.9 of the issues and Europe over 2.2% of the cases.

In 2021, there were an assessed 1.4 million deaths in HIV-negative individuals and around 187 000 in HIV-positive individuals, for an integrated sum of 1.6 million, which was elevated from the most reasonable assessments of 1.5 million in 2020 and 1.4 million in 2019, and around to the level of 2017.

The Increasing Increasing Research Funding is Expected To Present The Global Antibiotics Market With Growth Opportunities

The increasing research funding is presenting the global antibiotics market with lucrative growth opportunities in the future. For instance, in June 2022, The UK government's Global AMR Innovation Fund (GAMRIF) funded £4.5 million to sustain the Global Antibiotic Research and Development Partnership (GARDP) to design unique therapies for drug-resistant disorders recognized by the World Health Organization as the most significant danger to global health and development.

The Antimicrobial Resistance Is Estimated To Hamper The Global Antibiotics Market During The Forecast Period

The antibiotic resistance and rarer players interested in active research are anticipated to hamper the growth of the antibiotics market over the forecast period. For instance, the 2021 WHO report represented the antibacterial clinical and preclinical pipeline as stationary and distant from satisfying multinational requirements. Since 2017 just 12 antibiotics have been authorized, 10 of which are from the existing categories with specified mechanisms of antimicrobial resistance (AMR).

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis.

War anywhere applies the bases for outbreaks and epidemics of communicable infections, from cholera in Yemen, to polio in Syria, and measles in Afghanistan. Indeed, both world wars induced a profound gain in TB deaths. Wars guide to circumstances that are the excellent breeding environment for TB, such as food insecurity and overcrowding in inadequately fanned areas.

This is the alarming condition presently encountering multiple individuals in bomb shelters across Ukraine. Wars destroy healthcare infrastructure, crush immunization programs, and restrict access to quality care. This indicates sick individuals frequently have late diagnoses, resulting in more harmful intricacies and a more significant possibility of onward transmission.

Segment Analysis

The Global Antibiotics Market is segmented based on drug class, spectrum, distribution channels, and region.

Owing To The Increasing Positive Research Outcomes The Carbapenem Drug Class Segment Is Estimated To Hold About 28.9% of the Global Market Share By 2030

Owing to the increasing positive research outcomes, the carbapenem drug class segment is estimated to hold 28.9% of the global antibiotic market share in the forecast period. For instance, in April 2022, data from a phase 3 clinical investigation publicized in the New England Journal of Medicine demonstrated that an oral carbapenem antibiotic might be a choice in treating complicated urinary tract infections (cUTIs) induced by multidrug-resistant bacteria.

Geographical Analysis

Asia-Pacific is estimated to hold 27.6% of the Market Share Owing to the Growing Infectious Diseases Prevalence in this Region.

Owing to the increasing prevalence and presence of a majority of key market players in this region the Asia Pacific market is estimated to exhibit a high shareholding 0f 28.7% in 2030. For instance, according to the WHO 2021 report, South-East Asia accounted for 43% of the assessed TB patients worldwide in 2020 over any different WHO region.

India had 26.0% of TB cases globally, China had 8.5% of the TB cases globally, Indonesia had 8.4% of the cases, the Philippines had 6.0% of the cases, Pakistan had 5.8% of the cases, and Bangladesh had 3.6% of the cases, holding in the sense that these nations and territories also had important decreases in the reporting of patients because of the COVID-19 pandemic. Although HIV preponderance is down, the number of individuals living with HIV increased to over 2.2 million in reporting nations and territories in 2021 because of Asia-Pacific's large population.

Competitive Landscape

The major global players in the antibiotics market include: GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, and Otsuka Pharmaceutical Co. Ltd among others.

Why Purchase the Report?

  • To visualize the Global Antibiotics Market segmentation based on drug class, spectrum, distribution channels, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antibiotics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Antibiotics Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Spectrum
  • 3.3. Snippet by Distribution Channels
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. New Product Developments
      • 4.1.1.2. Growing Prevalence of Infectious Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Antimicrobial Resistance
    • 4.1.3. Opportunity
      • 4.1.3.1. Funding Initiatives
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Cephalosporin *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Penicillin
  • 7.4. Fluoroquinolones
  • 7.5. Carbapenem
  • 7.6. Macrolides
  • 7.7. Sulfonamides
  • 7.8. Aminoglycosides
  • 7.9. Others

8. By Spectrum

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 8.1.2. Market Attractiveness Index, By Spectrum
  • 8.2. Narrow-spectrum Antibiotics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Broad-spectrum Antibiotics

9. By Distribution Channels

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.1.2. Market Attractiveness Index, By Distribution Channels
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GlaxoSmithKline PLC
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Johnson & Johnson Inc.
  • 12.3. Merck & Co. Inc.
  • 12.4. Pfizer Inc.
  • 12.5. Bayer Healthcare AG
  • 12.6. Novartis AG
  • 12.7. Sanofi SA
  • 12.8. Abbott Laboratories
  • 12.9. F. Hoffmann-La Roche AG
  • 12.10. Otsuka Pharmaceutical Co. Ltd

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us